These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30426615)

  • 1. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.
    Liang C; Ma Y; Yong L; Yang C; Wang P; Liu X; Zhu B; Zhou H; Liu X; Liu Z
    Cancer Sci; 2019 Jan; 110(1):166-179. PubMed ID: 30426615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
    Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
    J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.
    de Castro CV; Guimaraes G; Aguiar S; Lopes A; Baiocchi G; da Cunha IW; Campos AH; Soares FA; Begnami MD
    Hum Pathol; 2013 Sep; 44(9):1747-55. PubMed ID: 23618355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia.
    Li H; Zhang D; Fu Q; Wang S; Wang Z; Zhang X; Chen X; Zhu X; An N; Chen Y; Zhou L; Lu D; Zhao N
    Blood Adv; 2023 Sep; 7(17):4874-4885. PubMed ID: 37339496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.
    Zhao S; Wang Y; Guo T; Yu W; Li J; Tang Z; Yu Z; Zhao L; Zhang Y; Wang Z; Wang P; Li Y; Li F; Sun Z; Xuan Y; Tang R; Deng WG; Guo W; Gu C
    Oncotarget; 2016 Dec; 7(50):82139-82157. PubMed ID: 27384875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of CDH1 up-regulates epidermal growth factor receptor via phosphorylation of YBX1 in non-small cell lung cancer cells.
    Liu X; Su L; Liu X
    FEBS Lett; 2013 Dec; 587(24):3995-4000. PubMed ID: 24211838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAGLN2 induces resistance signature ISGs by activating AKT-YBX1 signal with dual pathways and mediates the IFN-related DNA damage resistance in gastric cancer.
    Zhuo H; Hou J; Hong Z; Yu S; Peng H; Zhang L; Xie W; Hong X
    Cell Death Dis; 2024 Aug; 15(8):608. PubMed ID: 39168971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldolase A promotes proliferation and G
    Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
    Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker.
    Zhao X; Liu Y; Yu S
    Biochim Biophys Acta Mol Basis Dis; 2017 Jul; 1863(7):1805-1816. PubMed ID: 28428004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1- NF-κB signaling axis.
    Wang Y; Su J; Wang Y; Fu D; Ideozu JE; Geng H; Cui Q; Wang C; Chen R; Yu Y; Niu Y; Yue D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):386. PubMed ID: 31481087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.
    Magnaghi P; Salom B; Cozzi L; Amboldi N; Ballinari D; Tamborini E; Gasparri F; Montagnoli A; Raddrizzani L; Somaschini A; Bosotti R; Orrenius C; Bozzi F; Pilotti S; Galvani A; Sommer J; Stacchiotti S; Isacchi A
    Mol Cancer Ther; 2018 Mar; 17(3):603-613. PubMed ID: 29237806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RP11-296E3.2 acts as an important molecular chaperone for YBX1 and promotes colorectal cancer proliferation and metastasis by activating STAT3.
    Shi Q; He Y; He S; Li J; Xia J; Chen T; Huo L; Ling Y; Liu Q; Zang W; Wang Q; Tang C; Wang X
    J Transl Med; 2023 Jun; 21(1):418. PubMed ID: 37370092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
    Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
    J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1.
    Lin Y; Zhang J; Li Y; Guo W; Chen L; Chen M; Chen X; Zhang W; Jin X; Jiang M; Xiao H; Wang C; Song C; Fu F
    J Transl Med; 2022 Jan; 20(1):17. PubMed ID: 34991621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1.
    Zhou X; Zhang K; Wang C; Teng Y; Yu P; Cai W; Gao W; Li M; Ding Y; Sun P; Chen F; Wang Y; Ma J; Maeshige N; Ma X; Li Q; Liang X; Zhang Y; Su D
    Cancer Lett; 2024 May; 590():216868. PubMed ID: 38593920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
    Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
    IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. USP18 promotes breast cancer growth by upregulating EGFR and activating the AKT/Skp2 pathway.
    Tan Y; Zhou G; Wang X; Chen W; Gao H
    Int J Oncol; 2018 Jul; 53(1):371-383. PubMed ID: 29749454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-targeting CK2α and YBX1 suppresses tumor progression by coordinated inhibition of the PI3K/AKT signaling pathway.
    Xu WF; Ma YC; Ma HS; Shi L; Mu H; Ou WB; Peng J; Li TT; Qin T; Zhou HM; Fu XQ; Li XH
    Cell Cycle; 2019 Dec; 18(24):3472-3490. PubMed ID: 31713447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer.
    Kuwano M; Shibata T; Watari K; Ono M
    Cancer Sci; 2019 May; 110(5):1536-1543. PubMed ID: 30903644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.